神経学臨床試験の世界市場

神経学臨床試験の世界市場は2030年までに73億米ドルに達する見込み

2024年に57億米ドルと推定される神経学臨床試験の世界市場は、2024年から2030年にかけてCAGR 4.3％で成長し、2030年には73億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるフェーズiは、CAGR 5.4%を記録し、分析期間終了時には30億米ドルに達すると予測されます。フェーズIIセグメントの成長率は、分析期間中CAGR 3.0%と推定されます。

米国市場は15億米ドルと推定、中国はCAGR 8.1％で成長予測

米国の神経学臨床試験市場は2024年に15億米ドルと推定されます。世界第2位の経済大国である中国は、2024年から2030年の分析期間においてCAGR 8.1%で推移し、2030年には15億米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.7%と3.4%と予測されています。欧州では、ドイツがCAGR 2.5%で成長すると予測されています。

世界の神経学臨床試験市場- 主要動向と促進要因のまとめ

神経学臨床試験が医薬品開発で重要性を増す理由とは？

神経学臨床試験は医学研究の最前線にあり、アルツハイマー病、パーキンソン病、多発性硬化症、てんかん、脳卒中など、幅広い神経疾患に対する新規治療法の発見を後押ししています。神経疾患の複雑さと多因子性を考慮すると、臨床試験は新しい治療法の検証、疾患修飾療法の評価、症状管理の改善において重要な役割を果たしています。神経内科における精密医療、遺伝子治療、生物製剤の急速な拡大により、それらの安全性と有効性を評価するための強固な臨床試験の必要性がさらに高まっています。神経学における従来の薬剤開発アプローチは、中枢神経系（CNS）へのドラッグデリバリーを制限する血液脳関門のために、しばしば挫折に直面してきました。しかし、ナノテクノロジー、バイオマーカーに基づく患者層別化、標的ドラッグデリバリーシステムなどの進歩により、神経学試験の成功率は向上しています。さらに、AIを活用した臨床試験デザインと患者募集戦略の登場により、臨床試験の効率が最適化され、コストが削減され、スケジュールが早まっています。神経変性疾患や神経疾患の世界の負担が増大する中、アンメット・メディカル・ニーズに対応し、神経科学治療薬の未来を形作る上で、アンメット・キーワードは不可欠な存在であり続ける。

神経学臨床試験の進歩を遅らせている課題とは？

神経学臨床試験は、その重要性が増しているにもかかわらず、その進歩や成功率を妨げるいくつかの課題に直面しています。最も根強い問題の一つは、失敗率の高さであり、多くの神経疾患治療薬候補が後期臨床試験で有効性を実証できず、製薬企業に大きな経済的損失をもたらしています。神経疾患の複雑さに加え、認知的・機能的転帰を客観的に測定することの難しさが、エンドポイントの決定や試験デザインに課題を投げかけています。神経学的試験は、長い試験期間、頻繁な評価、腰椎穿刺や脳画像診断などの侵襲的な処置を必要とすることが多く、参加意欲を減退させる可能性があるため、患者のリクルートとリテンションは依然として大きなボトルネックとなっています。さらに、神経疾患は異質であるため、適切な患者集団を特定することが難しく、バイオマーカーを活用した高度な層別化アプローチが必要となります。神経学的臨床試験の規制状況も厳しく、中枢神経系を標的とした治療にはリスクが伴うため、各機関は広範な安全性データを要求します。特にアルツハイマー病やALSのような疾患では、認知機能の低下がインフォームド・コンセントや患者のコンプライアンスに影響を及ぼす可能性があるため、倫理的な配慮が臨床試験の実施をさらに複雑にしています。このような課題に対処するためには、革新的な調査手法、採用戦略の改善、より迅速で効果的な規制の枠組みの強化が必要です。

技術革新はどのように神経学臨床試験を変革するのか？

神経学臨床試験市場は、効率性、正確性、アクセシビリティを向上させる最先端の技術革新により、技術革命を経験しています。最もインパクトのある進歩のひとつは、デジタルバイオマーカーとウェアラブルテクノロジーの統合であり、これによって神経機能のリアルタイムモニタリングが可能になり、客観的かつ継続的なデータ収集が可能になりました。AIと機械学習も神経学臨床試験で極めて重要な役割を果たしており、患者募集の合理化、治療反応の予測、臨床試験エンドポイントの最適化を実現しています。バーチャル臨床試験や分散型臨床試験（DCT）は勢いを増しており、直接訪問する必要性を減らし、従来の地理的制限を超えて患者の参加を拡大しています。機能的MRI（fMRI）、拡散テンソル画像（DTI）、PETスキャンなどの高度な神経画像技術は、疾患の進行や治療効果をより正確に追跡する能力を高めています。さらに、患者特異的オルガノイドモデルや体外神経疾患モデルの開発により、前臨床創薬が加速し、従来の動物モデルへの依存度が低下しています。臨床試験データ管理におけるブロックチェーン技術の台頭も、神経学研究における透明性、データの完全性、患者の信頼を向上させています。このような技術的進歩が進化を続ける中、神経学臨床試験はより効率的でスケーラブルになり、複雑な神経疾患に対する画期的な治療法を提供できるようになってきています。

神経学臨床試験市場の成長の原動力は？

神経学臨床試験市場の成長は、神経疾患の有病率の上昇、神経科学研究への投資の増加、精密医療の進歩など、いくつかの要因によってもたらされます。アルツハイマー病、パーキンソン病、てんかん、希少神経疾患の世界の増加により、効果的な治療に対する緊急のニーズが生まれ、製薬会社や研究機関は臨床試験への取り組みを加速させています。神経科学研究を支援することを目的とした政府のイニシアティブや資金提供プログラムも市場開拓に拍車をかけており、規制当局は中枢神経系を標的とした新規治療法の開発にインセンティブを与えています。バイオマーカー主導型臨床試験へのシフトも主要な促進要因であり、より優れた患者層別化を可能にし、試験の成功率を向上させています。分散型臨床試験やバーチャル臨床試験プラットフォームの拡大により、アクセス性がさらに向上し、より多様な患者集団が神経学研究に参加できるようになっています。さらに、バイオテクノロジー企業、学術機関、開発業務受託機関（CRO）の連携が、試験デザインと実施におけるイノベーションを促進しています。人工知能、ニューロイメージング、デジタルヘルス技術が臨床試験の展望を再構築し続ける中、神経学分野は大きな進歩を遂げ、衰弱性神経疾患に苦しむ患者に新たな希望を提供する態勢が整っています。

セグメント

フェーズタイプ（フェーズi、フェーズII、フェーズIII、フェーズIV）、試験デザインタイプ（介入試験デザイン、観察試験デザイン、拡大アクセス試験デザイン）、適応症タイプ（てんかん、パーキンソン病、ハンチントン病、脳卒中、外傷性脳損傷、筋萎縮性側索硬化症、筋再生、その他の適応症タイプ）

調査対象企業の例

• AbbVie Inc.
• Athira Pharma, Inc.
• Aurora Health Care
• Biogen Inc.
• Charles River Laboratories International, Inc.
• Clarity Pharmaceuticals Ltd
• EBR Systems, Inc.
• Eisai Co., Ltd.
• GlaxoSmithKline plc
• ICON plc
• IQVIA Holdings Inc.
• Medpace Holdings, Inc.
• Merck & Co., Inc.
• Neuren Pharmaceuticals Limited
• Novartis International AG
• PPD（Thermo Fisher Scientific Inc.）
• PYC Therapeutics Limited
• Sanofi S.A.
• Syneos Health
• Telix Pharmaceuticals Limited

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Neurology Clinical Trials Market to Reach US$7.3 Billion by 2030

The global market for Neurology Clinical Trials estimated at US$5.7 Billion in the year 2024, is expected to reach US$7.3 Billion by 2030, growing at a CAGR of 4.3% over the analysis period 2024-2030. Phase I, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$3.0 Billion by the end of the analysis period. Growth in the Phase II segment is estimated at 3.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.5 Billion While China is Forecast to Grow at 8.1% CAGR

The Neurology Clinical Trials market in the U.S. is estimated at US$1.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.5 Billion by the year 2030 trailing a CAGR of 8.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.7% and 3.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.5% CAGR.

Global Neurology Clinical Trials Market - Key Trends & Drivers Summarized

Why Are Neurology Clinical Trials Gaining Importance in Drug Development?

Neurology clinical trials are at the forefront of medical research, driving the discovery of novel therapies for a wide range of neurological disorders, including Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, epilepsy, and stroke. Given the complexity and multifactorial nature of neurological conditions, clinical trials play a crucial role in validating new treatments, assessing disease-modifying therapies, and improving symptom management. The rapid expansion of precision medicine, gene therapy, and biologics in neurology has further amplified the need for robust clinical trials to evaluate their safety and efficacy. Traditional drug development approaches in neurology have often faced setbacks due to the blood-brain barrier, which limits drug delivery to the central nervous system (CNS). However, advances in nanotechnology, biomarker-based patient stratification, and targeted drug delivery systems are now enhancing the success rates of neurology trials. Additionally, the emergence of AI-driven clinical trial design and patient recruitment strategies is optimizing trial efficiency, reducing costs, and accelerating timelines. As the global burden of neurodegenerative and neurological disorders rises, neurology clinical trials remain essential in addressing unmet medical needs and shaping the future of neuroscience therapeutics.

What Challenges Are Slowing the Progress of Neurology Clinical Trials?

Despite their growing significance, neurology clinical trials face several challenges that hinder their progress and success rates. One of the most persistent issues is the high failure rate, with many neurology drug candidates failing to demonstrate efficacy in late-stage trials, leading to significant financial losses for pharmaceutical companies. The complexity of neurological diseases, coupled with the difficulty of measuring cognitive and functional outcomes objectively, poses challenges in endpoint determination and trial design. Patient recruitment and retention remain major bottlenecks, as neurological trials often require long study durations, frequent assessments, and invasive procedures such as lumbar punctures or brain imaging, which can discourage participation. Additionally, the heterogeneity of neurological disorders makes it difficult to identify suitable patient populations, requiring advanced biomarker-driven stratification approaches. The regulatory landscape for neurology trials is also stringent, with agencies requiring extensive safety data due to the risks associated with CNS-targeted therapies. Ethical considerations, particularly in conditions such as Alzheimer’s and ALS, further complicate trial execution, as cognitive decline can impact informed consent and patient compliance. Addressing these challenges requires innovative trial methodologies, improved recruitment strategies, and enhanced regulatory frameworks to facilitate faster and more effective neurology clinical trials.

How Are Technological Innovations Transforming Neurology Clinical Trials?

The neurology clinical trials market is experiencing a technological revolution, with cutting-edge innovations improving efficiency, accuracy, and accessibility. One of the most impactful advancements is the integration of digital biomarkers and wearable technologies, which allow real-time monitoring of neurological function, providing objective and continuous data collection. AI and machine learning are also playing a pivotal role in neurology trials, streamlining patient recruitment, predicting treatment responses, and optimizing trial endpoints. Virtual and decentralized clinical trials (DCTs) are gaining momentum, reducing the need for in-person visits and expanding patient participation beyond traditional geographic limitations. Advanced neuroimaging techniques such as functional MRI (fMRI), diffusion tensor imaging (DTI), and PET scans are enhancing the ability to track disease progression and treatment effects with greater precision. Additionally, the development of patient-specific organoid models and in-vitro neurological disease models is accelerating preclinical drug discovery, reducing reliance on traditional animal models. The rise of blockchain technology in clinical trial data management is also improving transparency, data integrity, and patient trust in neurology research. As these technological advancements continue to evolve, neurology clinical trials are becoming more efficient, scalable, and capable of delivering breakthrough therapies for complex neurological conditions.

What Is Driving the Growth of the Neurology Clinical Trials Market?

The growth in the neurology clinical trials market is driven by several factors, including the rising prevalence of neurological disorders, increasing investments in neuroscience research, and advancements in precision medicine. The global increase in Alzheimer’s disease, Parkinson’s disease, epilepsy, and rare neurological conditions has created an urgent need for effective treatments, prompting pharmaceutical companies and research institutions to accelerate clinical trial efforts. Government initiatives and funding programs aimed at supporting neuroscience research are also fueling market expansion, with regulatory agencies providing incentives for the development of novel CNS-targeted therapies. The shift toward biomarker-driven clinical trials is another key growth driver, enabling better patient stratification and improving trial success rates. The expansion of decentralized clinical trials and virtual trial platforms is further enhancing accessibility, allowing more diverse patient populations to participate in neurology studies. Additionally, collaborations between biotech firms, academic institutions, and contract research organizations (CROs) are driving innovation in trial design and execution. As artificial intelligence, neuroimaging, and digital health technologies continue to reshape the clinical trials landscape, the neurology sector is poised for significant advancements, offering new hope for patients suffering from debilitating neurological disorders.

SCOPE OF STUDY:

The report analyzes the Neurology Clinical Trials market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Phase Type (Phase I, Phase II, Phase III, Phase IV); Study Design Type (Interventional Study Design, Observational Study Design, Expanded Access Study Design); Indication Type (Epilepsy, Parkinson's Disease, Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• AbbVie Inc.
• Athira Pharma, Inc.
• Aurora Health Care
• Biogen Inc.
• Charles River Laboratories International, Inc.
• Clarity Pharmaceuticals Ltd
• EBR Systems, Inc.
• Eisai Co., Ltd.
• GlaxoSmithKline plc
• ICON plc
• IQVIA Holdings Inc.
• Medpace Holdings, Inc.
• Merck & Co., Inc.
• Neuren Pharmaceuticals Limited
• Novartis International AG
• PPD (Thermo Fisher Scientific Inc.)
• PYC Therapeutics Limited
• Sanofi S.A.
• Syneos Health
• Telix Pharmaceuticals Limited

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Neurology Clinical Trials - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of Neurological Disorders Spurs Demand for Innovative Clinical Trial Protocols
  • Aging Global Population Expands Addressable Market Opportunity for Neurology Trials
  • Precision Medicine and Biomarker-Based Approaches Drive Adoption of Stratified Neurology Trials
  • Increasing CNS Drug Pipeline Strengthens Business Case for Specialized Clinical Trial Services
  • Technological Advancements in Neuroimaging Tools Drive Data Accuracy and Trial Efficiency
  • Artificial Intelligence and Machine Learning Propel Growth of Predictive Analytics in Trial Design
  • Decentralized Clinical Trials Model Generates Demand for Remote Neurology Monitoring Solutions
  • Growing Investment in Neurodegenerative Disease Research Accelerates Demand for Early-Phase Trials
  • Regulatory Push for Real-World Evidence Integration Drives Adoption of Hybrid Clinical Trial Models
  • Emergence of Digital Biomarkers and Wearables Expands Market Scope for Patient-Centric Neurology Trials
  • Advances in Genomics and Proteomics Strengthen the Case for Personalized Neurology Interventions
  • Increasing Emphasis on Patient Recruitment and Retention Solutions Spurs Innovation in Trial Platforms
  • Globalization of Clinical Trials Opens Up New Geographies, Driving Market Expansion in Emerging Economies
  • FDA and EMA Initiatives to Expedite Neurology Drug Approval Pathways Sustain Growth Momentum
  • Public-Private Partnerships in Neuroscience Research Generate New Commercial Trial Opportunities
  • Blockchain Adoption in Clinical Data Management Enhances Transparency and Trust in Neurology Trials
  • Growing Role of Companion Diagnostics Drives Adoption of Targeted Neurology Therapies
  • Shift Toward Adaptive Trial Designs Propels Efficiency and Cost-Effectiveness in Neurology R&D
  • Rising Incidence of Mental Health Disorders Throws the Spotlight on Psychiatric Trial Innovations
  • Integration of Virtual Reality and Digital Therapeutics Drives Evolution of Cognitive Testing Methods
  • Increasing Payer Focus on Value-Based Outcomes Strengthens Demand for Evidence-Rich Trial Designs
  • Rising Cybersecurity Concerns Around Trial Data Management Create Challenges for Digital Trial Platforms
  • Expanding Use of Mobile Health Applications Enhances Patient Engagement and Trial Continuity
  • Shift Toward Diversity and Inclusion in Trial Participation Expands Patient Pool and Regulatory Compliance
  • Growing Role of Contract Research Organizations (CROs) Spurs Competitive Differentiation in Trial Services
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Neurology Clinical Trials Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Neurology Clinical Trials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Neurology Clinical Trials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Neurology Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Phase I by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Phase I by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Phase I by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Phase II by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Phase II by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Phase II by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Phase III by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Phase III by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Phase III by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Phase IV by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Phase IV by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Phase IV by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Huntington's Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Huntington's Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Huntington's Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Stroke by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Stroke by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Stroke by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Traumatic Brain Injury by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Traumatic Brain Injury by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Traumatic Brain Injury by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Amyotrophic Lateral Sclerosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Amyotrophic Lateral Sclerosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Muscle Regeneration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Muscle Regeneration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Muscle Regeneration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Other Indication Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Other Indication Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Other Indication Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Epilepsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Epilepsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Epilepsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Parkinson's Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Parkinson's Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Parkinson's Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Interventional Study Design by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Interventional Study Design by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for Interventional Study Design by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Observational Study Design by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Observational Study Design by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: World 15-Year Perspective for Observational Study Design by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for Expanded Access Study Design by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for Expanded Access Study Design by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: World 15-Year Perspective for Expanded Access Study Design by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Neurology Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 50: USA Recent Past, Current & Future Analysis for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: USA 15-Year Perspective for Neurology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 53: USA Recent Past, Current & Future Analysis for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: USA Historic Review for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: USA 15-Year Perspective for Neurology Clinical Trials by Indication Type - Percentage Breakdown of Value Sales for Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease for the Years 2015, 2025 & 2030
  • TABLE 56: USA Recent Past, Current & Future Analysis for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: USA Historic Review for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: USA 15-Year Perspective for Neurology Clinical Trials by Study Design Type - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 59: Canada Recent Past, Current & Future Analysis for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Canada Historic Review for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Canada 15-Year Perspective for Neurology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 62: Canada Recent Past, Current & Future Analysis for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Canada Historic Review for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Canada 15-Year Perspective for Neurology Clinical Trials by Indication Type - Percentage Breakdown of Value Sales for Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease for the Years 2015, 2025 & 2030
  • TABLE 65: Canada Recent Past, Current & Future Analysis for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Canada Historic Review for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Canada 15-Year Perspective for Neurology Clinical Trials by Study Design Type - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
• JAPAN
  • Neurology Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 68: Japan Recent Past, Current & Future Analysis for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Japan Historic Review for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Japan 15-Year Perspective for Neurology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 71: Japan Recent Past, Current & Future Analysis for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Japan Historic Review for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Japan 15-Year Perspective for Neurology Clinical Trials by Indication Type - Percentage Breakdown of Value Sales for Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease for the Years 2015, 2025 & 2030
  • TABLE 74: Japan Recent Past, Current & Future Analysis for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Japan Historic Review for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Japan 15-Year Perspective for Neurology Clinical Trials by Study Design Type - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
• CHINA
  • Neurology Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 77: China Recent Past, Current & Future Analysis for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: China Historic Review for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: China 15-Year Perspective for Neurology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 80: China Recent Past, Current & Future Analysis for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: China Historic Review for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: China 15-Year Perspective for Neurology Clinical Trials by Indication Type - Percentage Breakdown of Value Sales for Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease for the Years 2015, 2025 & 2030
  • TABLE 83: China Recent Past, Current & Future Analysis for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: China Historic Review for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: China 15-Year Perspective for Neurology Clinical Trials by Study Design Type - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
• EUROPE
  • Neurology Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 86: Europe Recent Past, Current & Future Analysis for Neurology Clinical Trials by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 87: Europe Historic Review for Neurology Clinical Trials by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Europe 15-Year Perspective for Neurology Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 89: Europe Recent Past, Current & Future Analysis for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Europe Historic Review for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Europe 15-Year Perspective for Neurology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 92: Europe Recent Past, Current & Future Analysis for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Europe Historic Review for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Europe 15-Year Perspective for Neurology Clinical Trials by Indication Type - Percentage Breakdown of Value Sales for Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease for the Years 2015, 2025 & 2030
  • TABLE 95: Europe Recent Past, Current & Future Analysis for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Europe Historic Review for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Europe 15-Year Perspective for Neurology Clinical Trials by Study Design Type - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
• FRANCE
  • Neurology Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 98: France Recent Past, Current & Future Analysis for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: France Historic Review for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: France 15-Year Perspective for Neurology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 101: France Recent Past, Current & Future Analysis for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: France Historic Review for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: France 15-Year Perspective for Neurology Clinical Trials by Indication Type - Percentage Breakdown of Value Sales for Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease for the Years 2015, 2025 & 2030
  • TABLE 104: France Recent Past, Current & Future Analysis for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: France Historic Review for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: France 15-Year Perspective for Neurology Clinical Trials by Study Design Type - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
• GERMANY
  • Neurology Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 107: Germany Recent Past, Current & Future Analysis for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Germany Historic Review for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Germany 15-Year Perspective for Neurology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 110: Germany Recent Past, Current & Future Analysis for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Germany Historic Review for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Germany 15-Year Perspective for Neurology Clinical Trials by Indication Type - Percentage Breakdown of Value Sales for Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease for the Years 2015, 2025 & 2030
  • TABLE 113: Germany Recent Past, Current & Future Analysis for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Germany Historic Review for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Germany 15-Year Perspective for Neurology Clinical Trials by Study Design Type - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 116: Italy Recent Past, Current & Future Analysis for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Italy Historic Review for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Italy 15-Year Perspective for Neurology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 119: Italy Recent Past, Current & Future Analysis for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Italy Historic Review for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Italy 15-Year Perspective for Neurology Clinical Trials by Indication Type - Percentage Breakdown of Value Sales for Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease for the Years 2015, 2025 & 2030
  • TABLE 122: Italy Recent Past, Current & Future Analysis for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Italy Historic Review for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Italy 15-Year Perspective for Neurology Clinical Trials by Study Design Type - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Neurology Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 125: UK Recent Past, Current & Future Analysis for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: UK Historic Review for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: UK 15-Year Perspective for Neurology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 128: UK Recent Past, Current & Future Analysis for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: UK Historic Review for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: UK 15-Year Perspective for Neurology Clinical Trials by Indication Type - Percentage Breakdown of Value Sales for Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease for the Years 2015, 2025 & 2030
  • TABLE 131: UK Recent Past, Current & Future Analysis for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: UK Historic Review for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: UK 15-Year Perspective for Neurology Clinical Trials by Study Design Type - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 134: Spain Recent Past, Current & Future Analysis for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Spain Historic Review for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Spain 15-Year Perspective for Neurology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 137: Spain Recent Past, Current & Future Analysis for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Spain Historic Review for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Spain 15-Year Perspective for Neurology Clinical Trials by Indication Type - Percentage Breakdown of Value Sales for Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease for the Years 2015, 2025 & 2030
  • TABLE 140: Spain Recent Past, Current & Future Analysis for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Spain Historic Review for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Spain 15-Year Perspective for Neurology Clinical Trials by Study Design Type - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 143: Russia Recent Past, Current & Future Analysis for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Russia Historic Review for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Russia 15-Year Perspective for Neurology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 146: Russia Recent Past, Current & Future Analysis for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Russia Historic Review for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Russia 15-Year Perspective for Neurology Clinical Trials by Indication Type - Percentage Breakdown of Value Sales for Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease for the Years 2015, 2025 & 2030
  • TABLE 149: Russia Recent Past, Current & Future Analysis for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Russia Historic Review for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Russia 15-Year Perspective for Neurology Clinical Trials by Study Design Type - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Rest of Europe Historic Review for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Rest of Europe 15-Year Perspective for Neurology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 155: Rest of Europe Recent Past, Current & Future Analysis for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Rest of Europe Historic Review for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Rest of Europe 15-Year Perspective for Neurology Clinical Trials by Indication Type - Percentage Breakdown of Value Sales for Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease for the Years 2015, 2025 & 2030
  • TABLE 158: Rest of Europe Recent Past, Current & Future Analysis for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Rest of Europe Historic Review for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Rest of Europe 15-Year Perspective for Neurology Clinical Trials by Study Design Type - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Neurology Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Neurology Clinical Trials by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 162: Asia-Pacific Historic Review for Neurology Clinical Trials by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Asia-Pacific 15-Year Perspective for Neurology Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Asia-Pacific Historic Review for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Asia-Pacific 15-Year Perspective for Neurology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 167: Asia-Pacific Recent Past, Current & Future Analysis for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Asia-Pacific Historic Review for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Asia-Pacific 15-Year Perspective for Neurology Clinical Trials by Indication Type - Percentage Breakdown of Value Sales for Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease for the Years 2015, 2025 & 2030
  • TABLE 170: Asia-Pacific Recent Past, Current & Future Analysis for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Asia-Pacific Historic Review for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Asia-Pacific 15-Year Perspective for Neurology Clinical Trials by Study Design Type - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Neurology Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 173: Australia Recent Past, Current & Future Analysis for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Australia Historic Review for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: Australia 15-Year Perspective for Neurology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 176: Australia Recent Past, Current & Future Analysis for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Australia Historic Review for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: Australia 15-Year Perspective for Neurology Clinical Trials by Indication Type - Percentage Breakdown of Value Sales for Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease for the Years 2015, 2025 & 2030
  • TABLE 179: Australia Recent Past, Current & Future Analysis for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Australia Historic Review for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: Australia 15-Year Perspective for Neurology Clinical Trials by Study Design Type - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
• INDIA
  • Neurology Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 182: India Recent Past, Current & Future Analysis for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: India Historic Review for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: India 15-Year Perspective for Neurology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 185: India Recent Past, Current & Future Analysis for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: India Historic Review for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: India 15-Year Perspective for Neurology Clinical Trials by Indication Type - Percentage Breakdown of Value Sales for Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease for the Years 2015, 2025 & 2030
  • TABLE 188: India Recent Past, Current & Future Analysis for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: India Historic Review for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: India 15-Year Perspective for Neurology Clinical Trials by Study Design Type - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 191: South Korea Recent Past, Current & Future Analysis for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: South Korea Historic Review for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: South Korea 15-Year Perspective for Neurology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 194: South Korea Recent Past, Current & Future Analysis for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: South Korea Historic Review for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: South Korea 15-Year Perspective for Neurology Clinical Trials by Indication Type - Percentage Breakdown of Value Sales for Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease for the Years 2015, 2025 & 2030
  • TABLE 197: South Korea Recent Past, Current & Future Analysis for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: South Korea Historic Review for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: South Korea 15-Year Perspective for Neurology Clinical Trials by Study Design Type - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 200: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Rest of Asia-Pacific Historic Review for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Rest of Asia-Pacific 15-Year Perspective for Neurology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 203: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Rest of Asia-Pacific Historic Review for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Rest of Asia-Pacific 15-Year Perspective for Neurology Clinical Trials by Indication Type - Percentage Breakdown of Value Sales for Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease for the Years 2015, 2025 & 2030
  • TABLE 206: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Rest of Asia-Pacific Historic Review for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Rest of Asia-Pacific 15-Year Perspective for Neurology Clinical Trials by Study Design Type - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Neurology Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 209: Latin America Recent Past, Current & Future Analysis for Neurology Clinical Trials by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 210: Latin America Historic Review for Neurology Clinical Trials by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Latin America 15-Year Perspective for Neurology Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 212: Latin America Recent Past, Current & Future Analysis for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Latin America Historic Review for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Latin America 15-Year Perspective for Neurology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 215: Latin America Recent Past, Current & Future Analysis for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Latin America Historic Review for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Latin America 15-Year Perspective for Neurology Clinical Trials by Indication Type - Percentage Breakdown of Value Sales for Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease for the Years 2015, 2025 & 2030
  • TABLE 218: Latin America Recent Past, Current & Future Analysis for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Latin America Historic Review for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Latin America 15-Year Perspective for Neurology Clinical Trials by Study Design Type - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 221: Argentina Recent Past, Current & Future Analysis for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Argentina Historic Review for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Argentina 15-Year Perspective for Neurology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 224: Argentina Recent Past, Current & Future Analysis for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Argentina Historic Review for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Argentina 15-Year Perspective for Neurology Clinical Trials by Indication Type - Percentage Breakdown of Value Sales for Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease for the Years 2015, 2025 & 2030
  • TABLE 227: Argentina Recent Past, Current & Future Analysis for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Argentina Historic Review for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Argentina 15-Year Perspective for Neurology Clinical Trials by Study Design Type - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 230: Brazil Recent Past, Current & Future Analysis for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Brazil Historic Review for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Brazil 15-Year Perspective for Neurology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 233: Brazil Recent Past, Current & Future Analysis for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Brazil Historic Review for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Brazil 15-Year Perspective for Neurology Clinical Trials by Indication Type - Percentage Breakdown of Value Sales for Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease for the Years 2015, 2025 & 2030
  • TABLE 236: Brazil Recent Past, Current & Future Analysis for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Brazil Historic Review for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Brazil 15-Year Perspective for Neurology Clinical Trials by Study Design Type - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 239: Mexico Recent Past, Current & Future Analysis for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Mexico Historic Review for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Mexico 15-Year Perspective for Neurology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 242: Mexico Recent Past, Current & Future Analysis for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Mexico Historic Review for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Mexico 15-Year Perspective for Neurology Clinical Trials by Indication Type - Percentage Breakdown of Value Sales for Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease for the Years 2015, 2025 & 2030
  • TABLE 245: Mexico Recent Past, Current & Future Analysis for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Mexico Historic Review for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Mexico 15-Year Perspective for Neurology Clinical Trials by Study Design Type - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 248: Rest of Latin America Recent Past, Current & Future Analysis for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Rest of Latin America Historic Review for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Rest of Latin America 15-Year Perspective for Neurology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 251: Rest of Latin America Recent Past, Current & Future Analysis for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Rest of Latin America Historic Review for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Rest of Latin America 15-Year Perspective for Neurology Clinical Trials by Indication Type - Percentage Breakdown of Value Sales for Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease for the Years 2015, 2025 & 2030
  • TABLE 254: Rest of Latin America Recent Past, Current & Future Analysis for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Rest of Latin America Historic Review for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Rest of Latin America 15-Year Perspective for Neurology Clinical Trials by Study Design Type - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Neurology Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 257: Middle East Recent Past, Current & Future Analysis for Neurology Clinical Trials by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 258: Middle East Historic Review for Neurology Clinical Trials by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Middle East 15-Year Perspective for Neurology Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 260: Middle East Recent Past, Current & Future Analysis for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Middle East Historic Review for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Middle East 15-Year Perspective for Neurology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 263: Middle East Recent Past, Current & Future Analysis for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Middle East Historic Review for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Middle East 15-Year Perspective for Neurology Clinical Trials by Indication Type - Percentage Breakdown of Value Sales for Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease for the Years 2015, 2025 & 2030
  • TABLE 266: Middle East Recent Past, Current & Future Analysis for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Middle East Historic Review for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Middle East 15-Year Perspective for Neurology Clinical Trials by Study Design Type - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 269: Iran Recent Past, Current & Future Analysis for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Iran Historic Review for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Iran 15-Year Perspective for Neurology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 272: Iran Recent Past, Current & Future Analysis for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Iran Historic Review for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Iran 15-Year Perspective for Neurology Clinical Trials by Indication Type - Percentage Breakdown of Value Sales for Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease for the Years 2015, 2025 & 2030
  • TABLE 275: Iran Recent Past, Current & Future Analysis for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Iran Historic Review for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Iran 15-Year Perspective for Neurology Clinical Trials by Study Design Type - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 278: Israel Recent Past, Current & Future Analysis for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Israel Historic Review for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Israel 15-Year Perspective for Neurology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 281: Israel Recent Past, Current & Future Analysis for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Israel Historic Review for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Israel 15-Year Perspective for Neurology Clinical Trials by Indication Type - Percentage Breakdown of Value Sales for Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease for the Years 2015, 2025 & 2030
  • TABLE 284: Israel Recent Past, Current & Future Analysis for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Israel Historic Review for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Israel 15-Year Perspective for Neurology Clinical Trials by Study Design Type - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 287: Saudi Arabia Recent Past, Current & Future Analysis for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Saudi Arabia Historic Review for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Saudi Arabia 15-Year Perspective for Neurology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 290: Saudi Arabia Recent Past, Current & Future Analysis for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Saudi Arabia Historic Review for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Saudi Arabia 15-Year Perspective for Neurology Clinical Trials by Indication Type - Percentage Breakdown of Value Sales for Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease for the Years 2015, 2025 & 2030
  • TABLE 293: Saudi Arabia Recent Past, Current & Future Analysis for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Saudi Arabia Historic Review for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Saudi Arabia 15-Year Perspective for Neurology Clinical Trials by Study Design Type - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 296: UAE Recent Past, Current & Future Analysis for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: UAE Historic Review for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: UAE 15-Year Perspective for Neurology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 299: UAE Recent Past, Current & Future Analysis for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: UAE Historic Review for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: UAE 15-Year Perspective for Neurology Clinical Trials by Indication Type - Percentage Breakdown of Value Sales for Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease for the Years 2015, 2025 & 2030
  • TABLE 302: UAE Recent Past, Current & Future Analysis for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: UAE Historic Review for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: UAE 15-Year Perspective for Neurology Clinical Trials by Study Design Type - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 305: Rest of Middle East Recent Past, Current & Future Analysis for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Rest of Middle East Historic Review for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Rest of Middle East 15-Year Perspective for Neurology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 308: Rest of Middle East Recent Past, Current & Future Analysis for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Rest of Middle East Historic Review for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Rest of Middle East 15-Year Perspective for Neurology Clinical Trials by Indication Type - Percentage Breakdown of Value Sales for Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease for the Years 2015, 2025 & 2030
  • TABLE 311: Rest of Middle East Recent Past, Current & Future Analysis for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Rest of Middle East Historic Review for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Rest of Middle East 15-Year Perspective for Neurology Clinical Trials by Study Design Type - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
• AFRICA
  • Neurology Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 314: Africa Recent Past, Current & Future Analysis for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Africa Historic Review for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 316: Africa 15-Year Perspective for Neurology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 317: Africa Recent Past, Current & Future Analysis for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Africa Historic Review for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 319: Africa 15-Year Perspective for Neurology Clinical Trials by Indication Type - Percentage Breakdown of Value Sales for Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease for the Years 2015, 2025 & 2030
  • TABLE 320: Africa Recent Past, Current & Future Analysis for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Africa Historic Review for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 322: Africa 15-Year Perspective for Neurology Clinical Trials by Study Design Type - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030

IV. COMPETITION